TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04386343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CH1701 for prevention and treatment of radiation burns.
Description: Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CH1701 for prevention and treatment of radiation burns.
Description: Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CH1701 for prevention and treatment of radiation burns.
Description: Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safety assessment of CH1701
Description: Safety assessment of CH1701 after 14 days of use on volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safety assessment of CH1701
Description: Safety assessment of CH1701 after 14 days of use on volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safety assessment of CH1701
Description: Safety assessment of CH1701 after 14 days of use on volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo was used on patients as a control for the doses of CH1701
Study: NCT02208154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral care (CHX-Oro)
Description: Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine oral care (CHX-Oro)
Description: Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective oropharyngeal decontamination (SOD)
Description: SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective oropharyngeal decontamination (SOD)
Description: SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Digestive Decontamination (SDD)
Description: SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective Digestive Decontamination (SDD)
Description: SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)
Study: NCT02601196

Intervention type: DRUG
Group type: OTHER
Intervention: Ulipristal acetate
Description: Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle.
Study: NCT02864420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospitalization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Hospitalization
Study: NCT00710281

Intervention type: RADIATION
Group type: OTHER
Intervention: Additional scan time on standard MR angiography
Description: Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:
Study: NCT02245126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-3-4 mix
Description: the drug mix included lidocaine, bupivacaine and water for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-4-2
Description: In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
Study: NCT00007917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02986334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
Study: NCT01197833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endovenous ablation+polidocanol injectable microfoam 0.125%
Description: All components except API

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endovenous ablation+polidocanol injectable microfoam 1.0%
Description: endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous ablation+polidocanol injectable foam 2.0%
Description: Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
Study: NCT01767207

Intervention type: OTHER
Intervention: mental disorders
Description: mental disorders

Intervention type: BEHAVIORAL
Intervention: screening for mental disorders
Description: screening for mental disorders
Study: NCT04439721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: γδT Cell infusion agent
Description: γδT
Study: NCT02736773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xenograft material to slow resorption
Description: xenograft material to slow resorption (Bio-Oss®)
Study: NCT00647673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCL Extended-Release Capsules 300 mg
Description: 300mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules 300 mg
Description: 300mg, single dose fasting
Study: NCT02077595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation, TENS
Description: Then participants will receive stimulation for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation, TENS
Description: Then participants will receive stimulation for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation, TENS
Description: Then participants will receive stimulation for 20 minutes.
Study: NCT01092000

Intervention type: BEHAVIORAL
Intervention: Monitoring
Description: Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.

Intervention type: BEHAVIORAL
Intervention: Monitoring
Description: Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.

Intervention type: BEHAVIORAL
Intervention: Monitoring
Description: Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.

Intervention type: OTHER
Intervention: Education
Description: Monthly exercise tips handout.

Intervention type: OTHER
Intervention: Education
Description: Monthly exercise tips handout.

Intervention type: OTHER
Intervention: Education
Description: Monthly exercise tips handout.
Study: NCT00571831

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: intraocular lens implantation
Description: Intraocular lens implantation
Study: NCT00832637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
Study: NCT04553042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.
Study: NCT03890419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green light
Description: Green light exposure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear light
Description: Full spectrum light exposure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light
Description: Blue light exposure
Study: NCT00337519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Description: see detailed description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
Study: NCT04047238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy
Description: Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~* Welcome to the patient and reality orientation therapy (7 minutes)~* Conducting the main activity of reminiscence (40 minutes)~* Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present.
Study: NCT00903955

Intervention type: OTHER
Intervention: 7% hypertonic saline
Description: Administered via jet nebulizer to subjects in specific aim 3
Study: NCT03425838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK 4/6 inhibitor
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK 4/6 inhibitor
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Steroidal Aromatase Inhibitor
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Steroidal Aromatase Inhibitor
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Study: NCT01246752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Stem Cell Transplantation
Description: Human allogenic stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
Description: Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
Study: NCT01978860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross, CTO
Description: evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
Study: NCT01933113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation of the Lateral Hypothalamic Area
Description: Deep Brain Stimulation of the Lateral Hypothalamic Area
Study: NCT04085627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan and Amlodipine Tablets
Description: 1 tablet contains Valsartan 80mg\& Amlodipine 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan and Amlodipine Tablets
Description: 1 tablet contains Valsartan 80mg\& Amlodipine 5mg
Study: NCT03278106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Description: Given PO
Study: NCT02255266

Intervention type: DRUG
Intervention: liraglutide
Description: No treatment given.
Study: NCT00978692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Orthokeratology lenses
Description: Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group

Intervention type: DEVICE
Group type: OTHER
Intervention: Single-vision spectacles
Description: Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
Study: NCT00221195

Intervention type: DRUG
Group type: OTHER
Intervention: activated prothrombin complex concentrate (FEIBA)
Description: FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: activated prothrombin complex concentrate (FEIBA)
Description: FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months
Study: NCT02116985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-loop TCI
Description: the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: manual
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
Study: NCT04426448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relaxation, Education And Trauma HEaling
Description: A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
Study: NCT02647866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: IV Infusion
Study: NCT00763035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
Study: NCT02647866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion
Study: NCT04588623

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omnibiotic Stress Repair (OBSR)
Description: OBSR is given orally once daily (3g) for 3 months
Study: NCT00763035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
Study: NCT04588623

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given orally once daily (3g) for 3 months
Study: NCT04367987

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
Study: NCT01267877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: read unfavorable article prior to answering questions
Description: article title: Taking a hit on healthcare- why that's women's work

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: read favorable article prior to answering questions
Description: read A Backlash of Mistrust
Study: NCT01369511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT00701220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
Study: NCT00353379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo for 6 weeks.